These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 15013938)

  • 1. Gut peptides in the treatment of diabetes mellitus.
    Vahl TP; D'Alessio DA
    Expert Opin Investig Drugs; 2004 Mar; 13(3):177-88. PubMed ID: 15013938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
    Meier JJ; Gallwitz B; Nauck MA
    BioDrugs; 2003; 17(2):93-102. PubMed ID: 12641488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
    Green BD; Gault VA; O'harte FP; Flatt PR
    Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
    Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
    Hansotia T; Drucker DJ
    Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid.
    Green BD; Gault VA; Flatt PR; Harriott P; Greer B; O'Harte FP
    Arch Biochem Biophys; 2004 Aug; 428(2):136-43. PubMed ID: 15246869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut peptides and type 2 diabetes mellitus treatment.
    Ahrén B
    Curr Diab Rep; 2003 Oct; 3(5):365-72. PubMed ID: 12975025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
    Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
    Baggio LL; Drucker DJ
    Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin hormone mimetics and analogues in diabetes therapeutics.
    Green BD; Flatt PR
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):497-516. PubMed ID: 18054732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005.
    Holst JJ
    Diabetologia; 2006 Feb; 49(2):253-60. PubMed ID: 16416146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.